Loading...
Citalopram — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Citalopram
2025-Q4
Comprehensive analysis of India’s citalopram export trade — suppliers, buyers, prices, routes, and every shipment record.
97
Shipments
$2.58M
Trade Value
16
Suppliers
27
Buyers
17
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/citalopram
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s citalopram trade — 2025-Q4
KEY TAKEAWAY
Citalopram 2025-Q4 exports total $2.6M across 17 countries, with TORRENT PHARMACEUTICALS LTD commanding 52.2% market share.
TOTAL SHIPMENTS
97
2025-Q4
EXPORT VALUE
$2.6M
FOB USD
TOTAL QUANTITY
88.5M
units shipped
INDIAN SUPPLIERS
16
unique exporters
GLOBAL BUYERS
27
unique importers
DESTINATIONS
17
countries
MEDIAN UNIT PRICE
$0.020
per unit
TOP-5 SHARE
90.9%
of total USD
BRANDED SHARE
38.1%
37 shipments
DOSAGE FORMS
2
product types
6 KEY FINDINGS
1
TORRENT PHARMACEUTICALS LTD is India's #1 Citalopram exporter with $1.3M (52.2% market share).→ §5, Indian Supplier Rankings
2
Citalopram reached 17 countries, with United States as the top destination ($1.8M).→ §4, Global Destination Map
3
Market concentration is high (HHI: 3234) — top 10 suppliers control 99.3% of exports.→ §5, Indian Supplier Rankings
4
92.6% of buyers (25 of 27) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (99.7%) across 2 dosage forms.→ §7, Price Benchmarks
6
17 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 TORRENT PHARMACEUTICALS LTD leads in volume — how do 16 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian citalopram exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Citalopram report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial citalopram trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian citalopram suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Citalopram India trade report
Product scope
Citalopram
All variants merged — branded and generic formulations of citalopram
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
97
Every commercial citalopram trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a steady rise: Oct $494.8K, Nov $605.8K, Dec $1.5M. Shipment counts rose across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$494.8K
Oct USD
18 shipments
2
$605.8K
Nov USD
+22.4% MoM
3
$1.5M
Dec USD
+143.9% MoM
4
Steady rise
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov rose 22.4% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $495K, making it the weakest month by value.
Fig 3.2 Q4 cumulative USD reached $2.6M.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $111K rise in Nov, $872K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Trade grew steadily across the quarter.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $495K | 18 shipments |
| Nov | $606K | 24 shipments |
| Dec | $1.5M | 55 shipments |
| Q4 Total | $2.6M | 97 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: United States held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: TORRENT PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import citalopram from India, how much they buy, and who supplies each market
KEY TAKEAWAY
United States absorbs 70.2% of India’s 2025-Q4 citalopram trade ($1.8M). Beyond the top 10 destinations, 17 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Europe has 7 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 17 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much citalopram India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$9K
0.3% of trade
2 countries · 10 shipments
Europe
$448K
17.4% of trade
7 countries · 36 shipments
Americas
$1.9M
74.9% of trade
4 countries · 30 shipments
Africa
$29K
1.1% of trade
3 countries · 3 shipments
Oceania
$162K
6.3% of trade
1 countries · 18 shipments
Fig 4.1 United States is the #1 corridor ($1.8M) — 17 flow arcs from India radiate across 5 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian citalopram it receives (light = low, dark = high). Orange arcs radiate from India to the top 17 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | $1.8M | 23 | TORRENT PHARMACEUTICALS LTD | $1.3M | AUROBINDO PHARMA LTD | $262K | MYLAN LABORATORIES LTD | $204K |
| 2 | Australia | $162K | 18 | STRIDES PHARMA SCIENCE LTD | $90K | IPCA LABORATORIES LTD | $72K | — | — |
| 3 | Hungary | $104K | 6 | MYLAN LABORATORIES LTD | $104K | — | — | — | — |
| 4 | United Kingdom | $103K | 3 | HETERO LABS LTD | $103K | — | — | — | — |
| 5 | Netherlands | $82K | 7 | MYLAN LABORATORIES LTD | $57K | HETERO LABS LTD | $25K | — | — |
| 6 | Malta | $78K | 16 | AUROBINDO PHARMA LTD | $78K | — | — | — | — |
| 7 | Brazil | $61K | 3 | ZYDUS LIFESCIENCES LTD | $61K | TORRENT PHARMACEUTICALS LTD | $44 | — | — |
| 8 | France | $46K | 2 | MYLAN LABORATORIES LTD | $33K | AUROBINDO PHARMA LTD | $13K | — | — |
| 9 | Canada | $30K | 3 | JUBILANT GENERICS LTD | $30K | — | — | — | — |
| 10 | Mexico | $29K | 1 | AUROBINDO PHARMA LTD | $29K | — | — | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 0.3% of USD — but United States is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
70.2%
#1 country share
United States alone
87.7%
Top 5 share
5 of 17 countries
100.0%
Top 15 share
Long tail of 2 countries = 0.0%
HHI 5038
Destination HHI
Highly concentrated
17
Countries served
Global pharma reach from India
7
Europe countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
16 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
TORRENT PHARMACEUTICALS LTD ($1.3M, 52.2% share) and MYLAN LABORATORIES LTD ($398.6K) together control 67.6% of India’s 2025-Q4 citalopram trade. The top 5 suppliers hold 90.9%. 16 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian citalopram suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 TORRENT PHARMACEUTICALS LTD leads by $947K over MYLAN LABORATORIES LTD — top 16 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: MOVID IMPEX is #15 by value but #5 by volume.
Fig 5.2 AUROBINDO PHARMA LTD also leads by shipment count (25) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: MOVID IMPEX moves from #5 by volume to #15 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 16 citalopram suppliers split into strategic segments
KEY TAKEAWAY
4 suppliers (25%) generate 87.4% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 TORRENT PHARMACEUTICALS LTD and MYLAN LABORATORIES LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 87.4% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | TORRENT PHARMACEUTICALS LTD | 1 | 2 | $1.3M |
| 2 | MYLAN LABORATORIES LTD | 1 | 4 | $399K |
| 3 | AUROBINDO PHARMA LTD | 1 | 4 | $382K |
| 4 | HETERO LABS LTD | 1 | 2 | $128K |
| 5 | STRIDES PHARMA SCIENCE LTD | 1 | 1 | $90K |
| 6 | IPCA LABORATORIES LTD | 1 | 1 | $72K |
| 7 | ZYDUS LIFESCIENCES LTD | 1 | 1 | $61K |
| 8 | JUBILANT GENERICS LTD | 1 | 1 | $30K |
| 9 | ADCOCK INGRAM LTD | 1 | 1 | $28K |
| 10 | MEDREICH LTD | 1 | 1 | $25K |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the citalopram manufacturing hubs
KEY TAKEAWAY
Kankaj Daskroi Ahmedabad and Nashik together account for $1.5M of India’s 2025-Q4 citalopram trade.
Fig 5.5 Kankaj Daskroi Ahmedabad (1 exporters, $1.1M) and Nashik (1 exporters, $399K) are India’s citalopram capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
90.9%
Top 5 share
5 of 16 suppliers
99.3%
Top 10 share
10 of 16 suppliers
87.4%
Top 25% share
4 suppliers = 87% USD
HHI 3234
Supplier HHI
Concentrated
16
Total suppliers
shipped Citalopram in 2025-Q4
14+ cities
Indian hubs
Kankaj Daskroi Ahmedabad and Nashik lead
§5.2 Coming next: 4 exporter deep-dive profiles
Each of the top 4 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
| #1 | TORRENT PHARMACEUTICALS LTD | $1.3M |
| #2 | MYLAN LABORATORIES LTD | $399K |
| #3 | AUROBINDO PHARMA LTD | $382K |
| #4 | HETERO LABS LTD | $128K |
#1
EXPORTER PROFILE #1 OF 4
TORRENT PHARMACEUTICALS LTD
Ahmedabad. Gujarat · India’s #1 citalopram supplier by USD · 2025-Q4
2025-Q4 USD
$1.3M
52.2% market share
SHIPMENTS
13
avg $103K/ship
COUNTRIES
2
destination markets
BUYERS
3
3 single-sourced
BRANDED
23%
of shipments
DOSAGE FORMS
1
product types
TOP 2 DESTINATIONS
United States is the #1 market at $1.3M (100% of trade), followed by Brazil at $44. 2 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | United States | $1.3M | 12 | 100.0% |
| 2 | Brazil | $44 | 1 | 0.0% |
MONTHLY TREND
Dec was the strongest month, ending the quarter on a high at $733K.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 3/3 LOCKED IN
3 of 3 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| TORRENT PHARMA INC | United States | $1.1M | ⚠ Locked |
| TORRENT PHARMA INCRXCR… | United States | $229K | ⚠ Locked |
| TORRENT DO BRASIL LTDA | Brazil | $44 | ⚠ Locked |
#1
EXPORTER PROFILE #1 OF 4 — TRADE FLOW MAP
TORRENT PHARMACEUTICALS LTD — Supplier → Country → Importer
2 destination countries, top 5 importers per country
Fig 5.P1.3 United States absorbs $1.3M — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 2 importers per destination.
#2
EXPORTER PROFILE #2 OF 4
MYLAN LABORATORIES LTD
Nashik · India’s #2 citalopram supplier by USD · 2025-Q4
2025-Q4 USD
$399K
15.5% market share
SHIPMENTS
16
avg $25K/ship
COUNTRIES
4
destination markets
BUYERS
5
5 single-sourced
BRANDED
31%
of shipments
DOSAGE FORMS
1
product types
TOP 4 DESTINATIONS
United States is the #1 market at $204K (51% of trade), followed by Hungary at $104K. 4 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | United States | $204K | 4 | 51.2% |
| 2 | Hungary | $104K | 6 | 26.0% |
| 3 | Netherlands | $57K | 5 | 14.4% |
| 4 | France | $33K | 1 | 8.4% |
MONTHLY TREND
Dec was the strongest month, ending the quarter on a high at $216K.
PRODUCT MIX
Tablet dominates at 98% of trade. Unknown (1.8%) and others are secondary formulations.
TOP BUYERS · 5/5 LOCKED IN
5 of 5 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| MYLAN PHARMACEUTICALS … | United States | $204K | ⚠ Locked |
| MYLAN HUNGARY KFT | Hungary | $104K | ⚠ Locked |
| MYLAN IRELAND LTD | Netherlands | $46K | ⚠ Locked |
| VIATRIS SA | France | $33K | ⚠ Locked |
| MYLAN B.V | Netherlands | $11K | ⚠ Locked |
#2
EXPORTER PROFILE #2 OF 4 — TRADE FLOW MAP
MYLAN LABORATORIES LTD — Supplier → Country → Importer
4 destination countries, top 5 importers per country
Fig 5.P2.3 United States absorbs $204K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
#3
EXPORTER PROFILE #3 OF 4
AUROBINDO PHARMA LTD
Hyderabad · India’s #3 citalopram supplier by USD · 2025-Q4
2025-Q4 USD
$382K
14.8% market share
SHIPMENTS
25
avg $15K/ship
COUNTRIES
4
destination markets
BUYERS
5
5 single-sourced
BRANDED
20%
of shipments
DOSAGE FORMS
1
product types
TOP 4 DESTINATIONS
United States is the #1 market at $262K (69% of trade), followed by Malta at $78K. 4 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | United States | $262K | 7 | 68.6% |
| 2 | Malta | $78K | 16 | 20.4% |
| 3 | Mexico | $29K | 1 | 7.7% |
| 4 | France | $13K | 1 | 3.4% |
MONTHLY TREND
Dec was the strongest month, ending the quarter on a high at $318K.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 5/5 LOCKED IN
5 of 5 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| AUROLOGISTICS LLC | United States | $156K | ⚠ Locked |
| AUROBINDO PHARMA USA INC | United States | $105K | ⚠ Locked |
| APL SWIFT SERVICES (MA… | Malta | $78K | ⚠ Locked |
| AUROVIDA FARMACEUTICA … | Mexico | $29K | ⚠ Locked |
| ARROW GENERIQUES | France | $13K | ⚠ Locked |
#3
EXPORTER PROFILE #3 OF 4 — TRADE FLOW MAP
AUROBINDO PHARMA LTD — Supplier → Country → Importer
4 destination countries, top 5 importers per country
Fig 5.P3.3 United States absorbs $262K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
#4
2025-Q4 USD
$128K
5.0% market share
SHIPMENTS
5
avg $26K/ship
COUNTRIES
2
destination markets
BUYERS
2
1 single-sourced
BRANDED
0%
of shipments
DOSAGE FORMS
1
product types
TOP 2 DESTINATIONS
United Kingdom is the #1 market at $103K (81% of trade), followed by Netherlands at $25K. 2 countries served.
| # | Country | USD | Ships | Share |
|---|---|---|---|---|
| 1 | United Kingdom | $103K | 3 | 80.6% |
| 2 | Netherlands | $25K | 2 | 19.4% |
MONTHLY TREND
Oct peaked at $103K. Dec was the weakest at $0.
PRODUCT MIX
Tablet dominates at 100% of trade.
TOP BUYERS · 1/1 LOCKED IN
1 of 1 buyers source exclusively from this supplier — high lock-in with low competitive threat.
| Buyer | Country | USD | Status |
|---|---|---|---|
| Undisclosed buyer | United Kingdom | $125K | N/A |
| AMAROX PHARMA B.V | Netherlands | $3K | ⚠ Locked |
#4
EXPORTER PROFILE #4 OF 4 — TRADE FLOW MAP
HETERO LABS LTD — Supplier → Country → Importer
2 destination countries, top 5 importers per country
Fig 5.P4.3 United Kingdom absorbs $103K — the thickest ribbon.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 2 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
27 importers across 17 countries — who is buying Indian citalopram and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 25 importers together hold only 92.4% of total USD. 93% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian citalopram. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 TORRENT PHARMA INC is the #1 importer at $1.1M (43.3%) — top 25 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 25 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
93%
Single-source
25 buyers rely on exactly 1 Indian supplier
7%
Dual-source
2 buyers use 2 Indian suppliers
0%
Multi-source (3–4)
0 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source citalopram from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 5 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| TORRENT PHARMA INC | TORRENT PHARMACEUTIC… | $1.1M | $3.828 | Tablet |
| TORRENT PHARMA INCRXCR… | TORRENT PHARMACEUTIC… | $229K | $5.369 | Tablet |
| MYLAN PHARMACEUTICALS … | MYLAN LABORATORIES LTD | $204K | $0.010 | Tablet |
| AUROLOGISTICS LLC | AUROBINDO PHARMA LTD | $156K | $0.0082 | Tablet |
| AUROBINDO PHARMA USA INC | AUROBINDO PHARMA LTD | $105K | $0.016 | Tablet |
Brazil 3 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| COSMED IND. DE COSM. M… | ZYDUS LIFESCIENCES LTD | $47K | $0.724 | Tablet |
| BRAINFARMA INDUSTRIA Q… | ZYDUS LIFESCIENCES LTD | $14K | $0.649 | Tablet |
| TORRENT DO BRASIL LTDA | TORRENT PHARMACEUTIC… | $44.287 | $0.035 | Tablet |
Netherlands 3 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| MYLAN IRELAND LTD | MYLAN LABORATORIES LTD | $46K | $0.013 | Tablet |
| MYLAN B.V | MYLAN LABORATORIES LTD | $11K | $0.020 | Tablet |
| AMAROX PHARMA B.V | HETERO LABS LTD | $3K | $0.022 | Tablet |
Australia 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| APOTEX PTY LTD | STRIDES PHARMA SCIEN… | $68K | $0.467 | Tablet |
| ARROW PHARMACEUTICALS … | STRIDES PHARMA SCIEN… | $21K | $0.418 | Tablet |
France 2 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| VIATRIS SA | MYLAN LABORATORIES LTD | $33K | $0.0090 | Tablet |
| ARROW GENERIQUES | AUROBINDO PHARMA LTD | $13K | $0.017 | Tablet |
§6.3 Price positioning — top 25 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | TORRENT PHARMA INC | United States | $1.1M | $124K | Premium |
| 2 | TORRENT PHARMA INCRX… | United States | $229K | $76K | Premium |
| 3 | MYLAN PHARMACEUTICAL… | United States | $204K | $51K | Premium |
| 4 | AUROLOGISTICS LLC | United States | $156K | $39K | Premium |
| 5 | AUROBINDO PHARMA USA… | United States | $105K | $35K | Premium |
| 6 | MYLAN HUNGARY KFT | Hungary | $104K | $17K | Mid |
| 7 | APL SWIFT SERVICES (… | Malta | $78K | $5K | Budget |
| 8 | APOTEX PTY LTD | Australia | $68K | $11K | Budget |
| 9 | COSMED IND. DE COSM.… | Brazil | $47K | $47K | Premium |
| 10 | MYLAN IRELAND LTD | Netherlands | $46K | $15K | Mid |
| 11 | VIATRIS SA | France | $33K | $33K | Mid |
| 12 | MINT PHARMACEUTICALS… | Canada | $30K | $10K | Budget |
| 13 | AUROVIDA FARMACEUTIC… | Mexico | $29K | $29K | Mid |
| 14 | OETHMAAN BIOSIMS PTY… | South Africa | $28K | $28K | Mid |
| 15 | LOGISTA PHARMA S.A | Spain | $25K | $25K | Mid |
| 16 | ARROW PHARMACEUTICAL… | Australia | $21K | $21K | Mid |
| 17 | BRAINFARMA INDUSTRIA… | Brazil | $14K | $14K | Budget |
| 18 | ARROW GENERIQUES | France | $13K | $13K | Budget |
| 19 | MYLAN B.V | Netherlands | $11K | $6K | Budget |
| 20 | YUSEN LOGISTICS BENE… | Belgium | $10K | $10K | Budget |
| 21 | RIGHT & BRIGHT INTER… | Myanmar | $9K | $9K | Budget |
| 22 | AMAROX PHARMA B.V | Netherlands | $3K | $3K | Budget |
| 23 | SHALINA HEALTHCARE S… | Tanzania | $568.401 | $568.000 | Budget |
| 24 | SURGIPHARM LTD | Kenya | $191.553 | $192.000 | Budget |
| 25 | TORRENT DO BRASIL LTDA | Brazil | $44.287 | $44.000 | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 16 × 20 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 TORRENT PHARMACEUTICALS LTD → TORRENT PHARMA INC is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 16 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian citalopram prices vary by supplier, country and dosage form
KEY TAKEAWAY
Citalopram prices span 50757× ($0.0002 → $9.90). The coefficient of variation is 2.48. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0002 | Lowest observed unit price |
| P5 | $0.0005 | 5th percentile |
| P25 | $0.014 | 25th percentile (Q1) |
| Median | $0.020 | 50th percentile (Q2) |
| P75 | $0.418 | 75th percentile (Q3) |
| P95 | $8.28 | 95th percentile |
| Max | $9.90 | Highest observed unit price |
| Mean | $0.913 | Arithmetic average |
| CV | 248% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 TORRENT PHARMACEUTICALS LTD prices at $5.04/unit vs market median $0.020.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. MYLAN LABORATORIES LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. TORRENT PHARMACEUTICALS LTD Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. SUN PHARMACEUTICAL INDUSTRIES Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. ZYDUS LIFESCIENCES LTD Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | JUBILANT GENERIC… | Canada | Tablet | 2K | $17K | $9.90 | Specialty / small-batch |
| Dec 2025 | TORRENT PHARMACE… | United States | Tablet | 12K | $101K | $8.59 | Specialty / small-batch |
| Nov 2025 | TORRENT PHARMACE… | United States | Tablet | 15K | $130K | $8.40 | Specialty / small-batch |
| Dec 2025 | TORRENT PHARMACE… | United States | Tablet | 16K | $130K | $8.35 | Specialty / small-batch |
| Oct 2025 | TORRENT PHARMACE… | United States | Tablet | 16K | $130K | $8.32 | Specialty / small-batch |
| Oct 2025 | TORRENT PHARMACE… | United States | Tablet | 8K | $64K | $8.27 | Specialty / small-batch |
| Dec 2025 | TORRENT PHARMACE… | United States | Tablet | 39K | $232K | $5.95 | Specialty / small-batch |
| Nov 2025 | TORRENT PHARMACE… | United States | Tablet | 16K | $90K | $5.81 | Specialty / small-batch |
| Dec 2025 | TORRENT PHARMACE… | United States | Tablet | 39K | $226K | $5.78 | Specialty / small-batch |
| Dec 2025 | JUBILANT GENERIC… | Canada | Tablet | 4K | $8K | $1.98 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Dec 2025 | DEEP IMPEX | United Arab Emirates | Tablet | 10 | $0.017 | $0.0017 | Bulk generic tablet |
| Dec 2025 | MYLAN LABORATORI… | United States | Tablet | 1.2M | $10K | $0.0085 | Bulk generic tablet |
| Nov 2025 | MYLAN LABORATORI… | Hungary | Tablet | 338K | $3K | $0.0085 | Bulk generic tablet |
| Nov 2025 | MYLAN LABORATORI… | France | Tablet | 3.7M | $33K | $0.0090 | Bulk generic tablet |
| Nov 2025 | MYLAN LABORATORI… | Hungary | Tablet | 3.6M | $33K | $0.0090 | Bulk generic tablet |
| Nov 2025 | MYLAN LABORATORI… | Hungary | Tablet | 3.7M | $33K | $0.0090 | Bulk generic tablet |
| Dec 2025 | MYLAN LABORATORI… | United States | Tablet | 5.3M | $51K | $0.0097 | Bulk generic tablet |
| Dec 2025 | AUROBINDO PHARMA… | Malta | Tablet | 634K | $6K | $0.0098 | Bulk generic tablet |
| Oct 2025 | AUROBINDO PHARMA… | United States | Tablet | 2.1M | $21K | $0.0099 | Bulk generic tablet |
| Nov 2025 | MYLAN LABORATORI… | Netherlands | Tablet | 2.5M | $25K | $0.0100 | Bulk generic tablet |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship citalopram, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Citalopram leaves India through 11+ ports. The top 5 (NHAVA SHEVA SEA (JNPT), HYDERABAD ICD, MUMBAI AIR (SAHAR)) handle 93.0% of total USD. SEA moves 35% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 NHAVA SHEVA SEA (JNPT) handles $1.6M — top 11 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 Norfolk is the #1 global destination port — top 25 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
SEA dominates at 35% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
SEA
$1.8M
69.0% of USD · 35.1% of ships
ICD
$568K
22.0% of USD · 29.9% of ships
AIR
$231K
9.0% of USD · 35.1% of ships
Fig 8.3 The dominant corridor is NHAVA SHEVA SEA (JNPT) → Sea → N. America ($1.5M).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
Malta is the most concentrated destination (HHI 10000, 1 suppliers). Australia is the most competitive (HHI 5059).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Malta (HHI 10,000) is the most concentrated — Australia (HHI 5,059) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 17 of 17 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| TORRENT PHARMA INC | United States | TORRENT PHARMACE… | $1.1M | 9 | CRITICAL |
| TORRENT PHARMA INCRX… | United States | TORRENT PHARMACE… | $229K | 3 | HIGH |
| MYLAN PHARMACEUTICAL… | United States | MYLAN LABORATORI… | $204K | 4 | HIGH |
| AUROLOGISTICS LLC | United States | AUROBINDO PHARMA… | $156K | 4 | HIGH |
| AUROBINDO PHARMA USA… | United States | AUROBINDO PHARMA… | $105K | 3 | HIGH |
| MYLAN HUNGARY KFT | Hungary | MYLAN LABORATORI… | $104K | 6 | HIGH |
| APL SWIFT SERVICES (… | Malta | AUROBINDO PHARMA… | $78K | 16 | MEDIUM |
| APOTEX PTY LTD | Australia | STRIDES PHARMA S… | $68K | 6 | MEDIUM |
Conclusion: 25 buyers depend on exactly one Indian supplier, representing $2.4M in trade. 1 are rated CRITICAL — if their sole supplier fails, they have no backup. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Australia | Tier 3 (emerging) | 3–5 days (air) | $0.10–$1/unit | LOW | First-mover advantage |
| Hungary | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| United Kingdom | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Netherlands | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Malta | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Brazil | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| France | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Canada | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Mexico | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| South Africa | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Spain | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Belgium | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Myanmar | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| Tanzania | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 13 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit Malta lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter Malta (1 suppliers) | This Q | HIGH |
| A6 | Enter United States (3 suppliers) | This Q | MED |
| A8 | Build Australia distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for United States tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | Malta | Other | 1 | $78K | +247481.3% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | United States | Other | 3 | $1.8M | +369.9% | LOW | Growing 370% with only 3 competitors |
| 3 | Australia | Other | 2 | $162K | -19.7% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | Hungary | Other | 1 | $104K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | United Kingdom | Other | 1 | $103K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Netherlands | Other | 2 | $82K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | Brazil | Other | 2 | $61K | 0% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | France | Other | 2 | $46K | -100% | LOW | Only 2 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Canada | Other | 1 | $30K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Mexico | Other | 1 | $29K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 11 | South Africa | Africa | 1 | $28K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 12 | Spain | Other | 1 | $25K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 13 | Belgium | Other | 1 | $10K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 14 | Myanmar | Asia | 1 | $9K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 15 | Tanzania | Africa | 1 | $568 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 97 2025-Q4 Citalopram shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/citalopram
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 97 2025-Q4 citalopram shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian citalopram shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
97
across all regions
TOTAL USD
$2.58M
2025-Q4 FOB value
UNITS
88.5M
tablets, capsules, etc.
SUPPLIERS
16
Indian exporters
BUYERS
27
global importers
COUNTRIES
17
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $29K (1.1%), spanning 3 countries.
16 Indian suppliers shipped to 27 buyers across 17 countries — average shipment value $27K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
3 countries · 3 shipments · $29K · 3 Indian suppliers · 3 buyers
SHIPMENTS
3
USD
$29K
COUNTRIES
3
SUPPLIERS
3
BUYERS
3
HHI
9,487
concentrated
Top 3 destination countries in Africa
1
South Africa (97.4%)
$28K
2
Tanzania (2.0%)
$568.40
3
Kenya (0.7%)
$191.55
Top 3 Indian suppliers into Africa
1
ADCOCK INGRAM LTD
$28K
2
SHALINA LABORATORIES PVT LTD
$568.40
3
IND SWIFT LTD
$191.55
Top 3 Africa importers
1
OETHMAAN BIOSIMS PTY LTD · South Africa
$28K
2
SHALINA HEALTHCARE SARL · Tanzania
$568.40
3
SURGIPHARM LTD · Kenya
$191.55
Top 2 dosage forms
1
Tablet
$28K
2
Syrup
$568.40
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 1 | $568.40 | $568.40 |
| Dec | 2 | $28K | $14K |
Shipment register · 3 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ADCOCK INGRAM LTD · 1 shipments · $28K | |||||||||||
| 1 | Dec 2025 | OETHMAAN BIOSIMS PTY LTD | South Africa | Tablet | 85.6K | NOS | $0.330 | $28K | BANGALORE ICD | DURBAN | ICD |
| SUPPLIER #2 — SHALINA LABORATORIES PVT LTD · 1 shipments · $568.40 | |||||||||||
| 2 | Nov 2025 | SHALINA HEALTHCARE SARL | Tanzania | Syrup | 2.8K | NOS | $0.206 | $568.40 | NHAVA SHEVA SEA (JNPT) | Dar Es Salaam | SEA |
| SUPPLIER #3 — IND SWIFT LTD · 1 shipments · $191.55 | |||||||||||
| 3 | Dec 2025 | SURGIPHARM LTD | Kenya | Tablet | 321.8K | NOS | $0.0006 | $191.55 | DELHI AIR | NAIROBI | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
2 countries · 10 shipments · $9K · 3 Indian suppliers · 2 buyers
SHIPMENTS
10
USD
$9K
COUNTRIES
2
SUPPLIERS
3
BUYERS
2
HHI
9,983
concentrated
Top 2 destination countries in Asia
1
Myanmar (99.9%)
$9K
2
United Arab Emirates (0.1%)
$7.28
Top 3 Indian suppliers into Asia
1
AMEGH PHARMA PVT LTD
$9K
2
MOVID IMPEX
$7.27
3
DEEP IMPEX
$0.017
Top 2 Asia importers
1
RIGHT & BRIGHT INTERNATIONAL CO LTD · Myanmar
$9K
2
EMIRATES POST GROUP · United Arab Emirates
$7.28
Top 2 dosage forms
1
Tablet
$9K
2
Unknown
$0.743
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 6 | $6.10 | $1.02 |
| Dec | 4 | $9K | $2K |
Shipment register · 10 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — AMEGH PHARMA PVT LTD · 1 shipments · $9K | |||||||||||
| 1 | Dec 2025 | RIGHT & BRIGHT INTERNATIONAL CO LTD | Myanmar | Tablet | 5.4K | NOS | $1.58 | $9K | MUMBAI AIR (SAHAR) | YANGON | AIR |
| SUPPLIER #2 — MOVID IMPEX · 8 shipments · $7.27 | |||||||||||
| 2 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 6 | NOS | $0.124 | $0.743 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 3 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | 6 | NOS | $0.124 | $0.743 | MUMBAI AIR (SAHAR) | DUBAI | AIR | |
| 4 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 8 | NOS | $0.128 | $1.02 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 5 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 10 | NOS | $0.128 | $1.28 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 6 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 8 | NOS | $0.128 | $1.02 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 7 | Nov 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 10 | NOS | $0.128 | $1.28 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 8 | Dec 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 8 | NOS | $0.130 | $1.04 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| 9 | Dec 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 1 | NOS | $0.130 | $0.130 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
| SUPPLIER #3 — DEEP IMPEX · 1 shipments · $0.017 | |||||||||||
| 10 | Dec 2025 | EMIRATES POST GROUP | United Arab Emirates | Tablet | 10 | NOS | $0.0017 | $0.017 | MUMBAI AIR (SAHAR) | DUBAI | AIR |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
7 countries · 36 shipments · $448K · 5 Indian suppliers · 10 buyers
SHIPMENTS
36
USD
$448K
COUNTRIES
7
SUPPLIERS
5
BUYERS
10
HHI
3,147
concentrated
Top 7 destination countries in Europe
1
Hungary (23.2%)
$104K
2
United Kingdom (23.0%)
$103K
3
Netherlands (18.3%)
$82K
4
Malta (17.4%)
$78K
5
France (10.4%)
$46K
6
Spain (5.7%)
$25K
7
Belgium (2.1%)
$10K
Top 5 Indian suppliers into Europe
1
MYLAN LABORATORIES LTD
$195K
2
HETERO LABS LTD
$128K
3
AUROBINDO PHARMA LTD
$91K
4
MEDREICH LTD
$25K
5
SUN PHARMACEUTICAL INDUSTRIES LTD
$10K
Top 9 Europe importers
1
MYLAN HUNGARY KFT · Hungary
$104K
2
APL SWIFT SERVICES (MALTA) LTD · Malta
$78K
3
MYLAN IRELAND LTD · Netherlands
$46K
4
VIATRIS SA · France
$33K
5
LOGISTA PHARMA S.A · Spain
$25K
6
ARROW GENERIQUES · France
$13K
7
MYLAN B.V · Netherlands
$11K
8
YUSEN LOGISTICS BENELUX BELGIUM · Belgium
$10K
9
AMAROX PHARMA B.V · Netherlands
$3K
Top 2 dosage forms
1
Tablet
$441K
2
Unknown
$7K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 6 | $125K | $21K |
| Nov | 12 | $208K | $17K |
| Dec | 18 | $115K | $6K |
Shipment register · 36 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — MYLAN LABORATORIES LTD · 12 shipments · $195K | |||||||||||
| 1 | Nov 2025 | VIATRIS SA | France | Tablet | 3.7M | NOS | $0.0090 | $33K | MUMBAI AIR (SAHAR) | PARIS - CHARLES DE G | AIR |
| 2 | Nov 2025 | MYLAN HUNGARY KFT | Hungary | Tablet | 3.6M | NOS | $0.0090 | $33K | MUMBAI AIR (SAHAR) | BUDAPEST, | AIR |
| 3 | Nov 2025 | MYLAN HUNGARY KFT | Hungary | Tablet | 338.2K | NOS | $0.0085 | $3K | MUMBAI AIR (SAHAR) | BUDAPEST, | AIR |
| 4 | Nov 2025 | MYLAN B.V | Netherlands | Tablet | 227.2K | NOS | $0.019 | $4K | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 5 | Nov 2025 | MYLAN HUNGARY KFT | Hungary | Tablet | 546.0K | NOS | $0.019 | $11K | MUMBAI AIR (SAHAR) | BUDAPEST, | AIR |
| 6 | Nov 2025 | MYLAN HUNGARY KFT | Hungary | Tablet | 3.7M | NOS | $0.0090 | $33K | MUMBAI AIR (SAHAR) | BUDAPEST, | AIR |
| 7 | Nov 2025 | MYLAN IRELAND LTD | Netherlands | Tablet | 476.2K | NOS | $0.024 | $11K | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 8 | Nov 2025 | MYLAN HUNGARY KFT | Hungary | Tablet | 1.1M | NOS | $0.019 | $22K | MUMBAI AIR (SAHAR) | BUDAPEST, | AIR |
| 9 | Nov 2025 | MYLAN IRELAND LTD | Netherlands | Tablet | 2.5M | NOS | $0.0100 | $25K | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 10 | Nov 2025 | MYLAN B.V | Netherlands | 351.3K | NOS | $0.020 | $7K | NHAVA SHEVA SEA (JNPT) | Rotterdam | SEA | |
| 11 | Dec 2025 | MYLAN IRELAND LTD | Netherlands | Tablet | 374.9K | NOS | $0.024 | $9K | MUMBAI AIR (SAHAR) | AMSTERDAM, SCHIPHOL | AIR |
| 12 | Dec 2025 | MYLAN HUNGARY KFT | Hungary | Tablet | 108.8K | NOS | $0.022 | $2K | MUMBAI AIR (SAHAR) | BUDAPEST, | AIR |
| SUPPLIER #2 — HETERO LABS LTD · 5 shipments · $128K | |||||||||||
| 13 | Oct 2025 | UNLISTED BUYER | United Kingdom | Tablet | 2.3M | NOS | $0.015 | $35K | SATTVA BENGALURU ICD, | SOUTHAMPTON | ICD |
| 14 | Oct 2025 | UNLISTED BUYER | United Kingdom | Tablet | 2.2M | NOS | $0.015 | $34K | SATTVA BENGALURU ICD, | SOUTHAMPTON | ICD |
| 15 | Oct 2025 | UNLISTED BUYER | United Kingdom | Tablet | 2.2M | NOS | $0.015 | $34K | SATTVA BENGALURU ICD, | SOUTHAMPTON | ICD |
| 16 | Nov 2025 | UNLISTED BUYER | Netherlands | Tablet | 1.1M | NOS | $0.020 | $22K | BANGALORE ICD | Rotterdam | ICD |
| 17 | Nov 2025 | AMAROX PHARMA B.V | Netherlands | Tablet | 141.1K | NOS | $0.022 | $3K | BANGALORE AIR | AMSTERDAM, SCHIPHOL | AIR |
| SUPPLIER #3 — AUROBINDO PHARMA LTD · 17 shipments · $91K | |||||||||||
| 18 | Oct 2025 | ARROW GENERIQUES | France | Tablet | 740.9K | NOS | $0.017 | $13K | HYDERABAD ICD | FOS SUR MER | ICD |
| 19 | Oct 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 2.0K | NOS | $0.016 | $31.40 | HYDERABAD AIR | MALTA | AIR |
| 20 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 152.8K | NOS | $0.019 | $3K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 21 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 302.4K | NOS | $0.017 | $5K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 22 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 90.0K | NOS | $0.016 | $1K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 23 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 75.0K | NOS | $0.017 | $1K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 24 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 325.2K | NOS | $0.021 | $7K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 25 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 205.8K | NOS | $0.020 | $4K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 26 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 36.3K | NOS | $0.021 | $755.02 | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 27 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 282.2K | NOS | $0.014 | $4K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 28 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 1.2M | NOS | $0.014 | $17K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 29 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 57.6K | NOS | $0.017 | $970.78 | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 30 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 155.0K | NOS | $0.015 | $2K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 31 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 538.0K | NOS | $0.014 | $8K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 32 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 144.0K | NOS | $0.011 | $2K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 33 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 1.5M | NOS | $0.010 | $15K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| 34 | Dec 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 634.0K | NOS | $0.0098 | $6K | HYDERABAD ICD | MALTA (VALETTA) | ICD |
| SUPPLIER #4 — MEDREICH LTD · 1 shipments · $25K | |||||||||||
| 35 | Dec 2025 | LOGISTA PHARMA S.A | Spain | Tablet | 80.9K | NOS | $0.314 | $25K | BANGALORE ICD | VALENCIA | ICD |
| SUPPLIER #5 — SUN PHARMACEUTICAL INDUSTRIES LTD · 1 shipments · $10K | |||||||||||
| 36 | Oct 2025 | YUSEN LOGISTICS BENELUX BELGIUM | Belgium | Tablet | 574.6K | NOS | $0.017 | $10K | DHANNAD ICD | ANTWERPEN | ICD |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
4 countries · 30 shipments · $1.93M · 5 Indian suppliers · 10 buyers
SHIPMENTS
30
USD
$1.93M
COUNTRIES
4
SUPPLIERS
5
BUYERS
10
HHI
5,203
concentrated
Top 4 destination countries in Americas
1
United States (93.8%)
$1.81M
2
Brazil (3.2%)
$61K
3
Canada (1.5%)
$30K
4
Mexico (1.5%)
$29K
Top 5 Indian suppliers into Americas
1
TORRENT PHARMACEUTICALS LTD
$1.35M
2
AUROBINDO PHARMA LTD
$291K
3
MYLAN LABORATORIES LTD
$204K
4
ZYDUS LIFESCIENCES LTD
$61K
5
JUBILANT GENERICS LTD
$30K
Top 10 Americas importers
1
TORRENT PHARMA INC · United States
$1.12M
2
TORRENT PHARMA INCRXCROSSROADS 3PL · United States
$229K
3
MYLAN PHARMACEUTICALS INC · United States
$204K
4
AUROLOGISTICS LLC · United States
$156K
5
AUROBINDO PHARMA USA INC · United States
$105K
6
COSMED IND. DE COSM. MED SA · Brazil
$47K
7
MINT PHARMACEUTICALS INC · Canada
$30K
8
AUROVIDA FARMACEUTICA SA DE CV · Mexico
$29K
9
BRAINFARMA INDUSTRIA QUIMICA E · Brazil
$14K
10
TORRENT DO BRASIL LTDA · Brazil
$44.29
Top 1 dosage forms
1
Tablet
$1.93M
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 5 | $280K | $56K |
| Nov | 5 | $397K | $79K |
| Dec | 20 | $1.25M | $63K |
Shipment register · 30 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — TORRENT PHARMACEUTICALS LTD · 13 shipments · $1.35M | |||||||||||
| 1 | Oct 2025 | TORRENT PHARMA INCRXCROSSROADS 3PL | United States | Tablet | 15.6K | NOS | $8.32 | $130K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 2 | Oct 2025 | TORRENT PHARMA INCRXCROSSROADS 3PL | United States | Tablet | 7.8K | NOS | $8.27 | $64K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 3 | Oct 2025 | TORRENT PHARMA INCRXCROSSROADS 3PL | United States | Tablet | 19.4K | NOS | $1.84 | $36K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 4 | Nov 2025 | TORRENT PHARMA INC | United States | Tablet | 15.6K | NOS | $5.81 | $90K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 5 | Nov 2025 | TORRENT PHARMA INC | United States | Tablet | 77.3K | NOS | $1.16 | $90K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 6 | Nov 2025 | TORRENT PHARMA INC | United States | Tablet | 39.1K | NOS | $1.86 | $73K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 7 | Nov 2025 | TORRENT PHARMA INC | United States | Tablet | 15.5K | NOS | $8.40 | $130K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 8 | Dec 2025 | TORRENT PHARMA INC | United States | Tablet | 39.0K | NOS | $5.78 | $226K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 9 | Dec 2025 | TORRENT PHARMA INC | United States | Tablet | 15.5K | NOS | $8.35 | $130K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 10 | Dec 2025 | TORRENT PHARMA INC | United States | Tablet | 38.9K | NOS | $1.16 | $45K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 11 | Dec 2025 | TORRENT DO BRASIL LTDA | Brazil | Tablet | 1.3K | NOS | $0.035 | $44.29 | NHAVA SHEVA SEA (JNPT) | Santos | SEA |
| 12 | Dec 2025 | TORRENT PHARMA INC | United States | Tablet | 39.0K | NOS | $5.95 | $232K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 13 | Dec 2025 | TORRENT PHARMA INC | United States | Tablet | 11.7K | NOS | $8.59 | $101K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| SUPPLIER #2 — AUROBINDO PHARMA LTD · 8 shipments · $291K | |||||||||||
| 14 | Oct 2025 | AUROVIDA FARMACEUTICA SA DE CV | Mexico | Tablet | 701.4K | NOS | $0.042 | $29K | HYDERABAD ICD | MANZANILLO | ICD |
| 15 | Oct 2025 | AUROBINDO PHARMA USA INC | United States | Tablet | 2.1M | NOS | $0.0099 | $21K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| 16 | Dec 2025 | AUROBINDO PHARMA USA INC | United States | Tablet | 830.4K | NOS | $0.020 | $17K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| 17 | Dec 2025 | AUROBINDO PHARMA USA INC | United States | Tablet | 3.5M | NOS | $0.019 | $68K | HYDERABAD ICD | NEWARK APT/NEW YORK | ICD |
| 18 | Dec 2025 | AUROLOGISTICS LLC | United States | Tablet | 422.4K | NOS | $0.0002 | $86.74 | DELHI AIR | NEW YORK - JOHN F. K | AIR |
| 19 | Dec 2025 | AUROLOGISTICS LLC | United States | Tablet | 5.8M | NOS | $0.0002 | $1K | DELHI AIR | NEW YORK - JOHN F. K | AIR |
| 20 | Dec 2025 | AUROLOGISTICS LLC | United States | Tablet | 8.0M | NOS | $0.013 | $106K | HYDERABAD ICD | NEW YORK | ICD |
| 21 | Dec 2025 | AUROLOGISTICS LLC | United States | Tablet | 4.8M | NOS | $0.010 | $49K | HYDERABAD ICD | NEWARK | ICD |
| SUPPLIER #3 — MYLAN LABORATORIES LTD · 4 shipments · $204K | |||||||||||
| 22 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 8.8M | NOS | $0.011 | $93K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 23 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 4.2M | NOS | $0.012 | $50K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 24 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 1.2M | NOS | $0.0085 | $10K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| 25 | Dec 2025 | MYLAN PHARMACEUTICALS INC | United States | Tablet | 5.3M | NOS | $0.0097 | $51K | NHAVA SHEVA SEA (JNPT) | Norfolk | SEA |
| SUPPLIER #4 — ZYDUS LIFESCIENCES LTD · 2 shipments · $61K | |||||||||||
| 26 | Nov 2025 | BRAINFARMA INDUSTRIA QUIMICA E | Brazil | Tablet | 21.9K | NOS | $0.649 | $14K | MUNDRA SEA | Santos | SEA |
| 27 | Dec 2025 | COSMED IND. DE COSM. MED SA | Brazil | Tablet | 65.2K | NOS | $0.724 | $47K | MUNDRA SEA | Santos | SEA |
| SUPPLIER #5 — JUBILANT GENERICS LTD · 3 shipments · $30K | |||||||||||
| 28 | Dec 2025 | MINT PHARMACEUTICALS INC | Canada | Tablet | 3.1K | NOS | $1.23 | $4K | DELHI AIR | Toronto | AIR |
| 29 | Dec 2025 | MINT PHARMACEUTICALS INC | Canada | Tablet | 1.7K | NOS | $9.90 | $17K | DELHI AIR | Toronto | AIR |
| 30 | Dec 2025 | MINT PHARMACEUTICALS INC | Canada | Tablet | 4.3K | NOS | $1.98 | $8K | DELHI AIR | Toronto | AIR |
10
PART VI — DRILL-DOWN · OCEANIA
Region: Oceania
1 countries · 18 shipments · $162K · 2 Indian suppliers · 3 buyers
SHIPMENTS
18
USD
$162K
COUNTRIES
1
SUPPLIERS
2
BUYERS
3
HHI
5,059
concentrated
Top 1 destination countries in Oceania
1
Australia (100.0%)
$162K
Top 2 Indian suppliers into Oceania
1
STRIDES PHARMA SCIENCE LTD
$90K
2
IPCA LABORATORIES LTD
$72K
Top 2 Oceania importers
1
APOTEX PTY LTD · Australia
$68K
2
ARROW PHARMACEUTICALS PTY LTD · Australia
$21K
Top 1 dosage forms
1
Tablet
$162K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 7 | $90K | $13K |
| Nov | 0 | $0.0000 | — |
| Dec | 11 | $72K | $7K |
Shipment register · 18 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — STRIDES PHARMA SCIENCE LTD · 7 shipments · $90K | |||||||||||
| 1 | Oct 2025 | APOTEX PTY LTD | Australia | Tablet | 31.2K | NOS | $0.418 | $13K | KATTUPALLI PORT SEA | Sydney | SEA |
| 2 | Oct 2025 | APOTEX PTY LTD | Australia | Tablet | 17.6K | NOS | $0.555 | $10K | KATTUPALLI PORT SEA | Sydney | SEA |
| 3 | Oct 2025 | APOTEX PTY LTD | Australia | Tablet | 31.2K | NOS | $0.418 | $13K | KATTUPALLI PORT SEA | Sydney | SEA |
| 4 | Oct 2025 | APOTEX PTY LTD | Australia | Tablet | 17.6K | NOS | $0.555 | $10K | KATTUPALLI PORT SEA | Sydney | SEA |
| 5 | Oct 2025 | APOTEX PTY LTD | Australia | Tablet | 31.2K | NOS | $0.418 | $13K | KATTUPALLI PORT SEA | Sydney | SEA |
| 6 | Oct 2025 | APOTEX PTY LTD | Australia | Tablet | 17.6K | NOS | $0.555 | $10K | KATTUPALLI PORT SEA | Sydney | SEA |
| 7 | Oct 2025 | ARROW PHARMACEUTICALS PTY LTD | Australia | Tablet | 50.8K | NOS | $0.418 | $21K | KATTUPALLI PORT SEA | Sydney | SEA |
| SUPPLIER #2 — IPCA LABORATORIES LTD · 11 shipments · $72K | |||||||||||
| 8 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 360.9K | NOS | $0.017 | $6K | NHAVA SHEVA SEA (JNPT) | Melbourne | SEA |
| 9 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 226.5K | NOS | $0.018 | $4K | NHAVA SHEVA SEA (JNPT) | Melbourne | SEA |
| 10 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 856.8K | NOS | $0.034 | $29K | NHAVA SHEVA SEA (JNPT) | Melbourne | SEA |
| 11 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 1.4M | TBS | $0.017 | $23K | NHAVA SHEVA SEA (JNPT) | Sydney | SEA |
| 12 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 230.5K | TBS | $0.034 | $8K | NHAVA SHEVA SEA (JNPT) | Sydney | SEA |
| 13 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 584.0K | TBS | $0.0000 | $0.0000 | MUMBAI AIR (SAHAR) | MELBOURNE | AIR |
| 14 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 564.5K | TBS | $0.0003 | $153.51 | MUMBAI AIR (SAHAR) | MELBOURNE | AIR |
| 15 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 2.2M | TBS | $0.0003 | $641.64 | MUMBAI AIR (SAHAR) | MELBOURNE | AIR |
| 16 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 584.0K | TBS | $0.0006 | $322.02 | MUMBAI AIR (SAHAR) | MELBOURNE | AIR |
| 17 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 2.4M | NOS | $0.0003 | $750.13 | NHAVA SHEVA SEA (JNPT) | Melbourne | SEA |
| 18 | Dec 2025 | UNLISTED BUYER | Australia | Tablet | 247.0K | TBS | $0.0005 | $135.17 | MUMBAI AIR (SAHAR) | SYDNEY | AIR |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 16 Indian citalopram exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped citalopram in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | TORRENT PHARMACEUTICALS LTD | AHMEDABAD. GUJARAT | 13 | $1.35M | Tablet | Americas |
| 2 | MYLAN LABORATORIES LTD | NASHIK | 16 | $399K | Tablet | Europe, Americas |
| 3 | AUROBINDO PHARMA LTD | HYDERABAD | 25 | $382K | Tablet | Europe, Americas |
| 4 | HETERO LABS LTD | KOLAR | 5 | $128K | Tablet | Europe |
| 5 | STRIDES PHARMA SCIENCE LTD | Bengaluru | 7 | $90K | Tablet | Oceania |
| 6 | IPCA LABORATORIES LTD | SILVASSA | 11 | $72K | Tablet | Oceania |
| 7 | ZYDUS LIFESCIENCES LTD | AHMEDABAD | 2 | $61K | Tablet | Americas |
| 8 | JUBILANT GENERICS LTD | DEHRADUN | 3 | $30K | Tablet | Americas |
| 9 | ADCOCK INGRAM LTD | BANGALORE | 1 | $28K | Tablet | Africa |
| 10 | MEDREICH LTD | BENGALURU | 1 | $25K | Tablet | Europe |
| 11 | SUN PHARMACEUTICAL INDUSTRIES LTD | MUMBAI | 1 | $10K | Tablet | Europe |
| 12 | AMEGH PHARMA PVT LTD | Mumbai | 1 | $9K | Tablet | Asia |
| 13 | SHALINA LABORATORIES PVT LTD | MUMBAI | 1 | $568.40 | Syrup | Africa |
| 14 | IND SWIFT LTD | MOHALI | 1 | $191.55 | Tablet | Africa |
| 15 | MOVID IMPEX | MUMBAI | 8 | $7.27 | Tablet | Asia |
| 16 | DEEP IMPEX | NAGPUR | 1 | $0.017 | Tablet | Asia |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 26 global citalopram importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian citalopram in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | TORRENT PHARMA INC | United States | 9 | $1.12M | TORRENT PHARMACEUTIC… | Tablet |
| 2 | TORRENT PHARMA INCRXCROSSROADS 3PL | United States | 3 | $229K | TORRENT PHARMACEUTIC… | Tablet |
| 3 | MYLAN PHARMACEUTICALS INC | United States | 4 | $204K | MYLAN LABORATORIES LTD | Tablet |
| 4 | AUROLOGISTICS LLC | United States | 4 | $156K | AUROBINDO PHARMA LTD | Tablet |
| 5 | AUROBINDO PHARMA USA INC | United States | 3 | $105K | AUROBINDO PHARMA LTD | Tablet |
| 6 | MYLAN HUNGARY KFT | Hungary | 6 | $104K | MYLAN LABORATORIES LTD | Tablet |
| 7 | APL SWIFT SERVICES (MALTA) LTD | Malta | 16 | $78K | AUROBINDO PHARMA LTD | Tablet |
| 8 | APOTEX PTY LTD | Australia | 6 | $68K | STRIDES PHARMA SCIEN… | Tablet |
| 9 | COSMED IND. DE COSM. MED SA | Brazil | 1 | $47K | ZYDUS LIFESCIENCES LTD | Tablet |
| 10 | MYLAN IRELAND LTD | Netherlands | 3 | $46K | MYLAN LABORATORIES LTD | Tablet |
| 11 | VIATRIS SA | France | 1 | $33K | MYLAN LABORATORIES LTD | Tablet |
| 12 | MINT PHARMACEUTICALS INC | Canada | 3 | $30K | JUBILANT GENERICS LTD | Tablet |
| 13 | AUROVIDA FARMACEUTICA SA DE CV | Mexico | 1 | $29K | AUROBINDO PHARMA LTD | Tablet |
| 14 | OETHMAAN BIOSIMS PTY LTD | South Africa | 1 | $28K | ADCOCK INGRAM LTD | Tablet |
| 15 | LOGISTA PHARMA S.A | Spain | 1 | $25K | MEDREICH LTD | Tablet |
| 16 | ARROW PHARMACEUTICALS PTY LTD | Australia | 1 | $21K | STRIDES PHARMA SCIEN… | Tablet |
| 17 | BRAINFARMA INDUSTRIA QUIMICA E | Brazil | 1 | $14K | ZYDUS LIFESCIENCES LTD | Tablet |
| 18 | ARROW GENERIQUES | France | 1 | $13K | AUROBINDO PHARMA LTD | Tablet |
| 19 | MYLAN B.V | Netherlands | 2 | $11K | MYLAN LABORATORIES LTD | Tablet |
| 20 | YUSEN LOGISTICS BENELUX BELGIUM | Belgium | 1 | $10K | SUN PHARMACEUTICAL I… | Tablet |
| 21 | RIGHT & BRIGHT INTERNATIONAL CO LTD | Myanmar | 1 | $9K | AMEGH PHARMA PVT LTD | Tablet |
| 22 | AMAROX PHARMA B.V | Netherlands | 1 | $3K | HETERO LABS LTD | Tablet |
| 23 | SHALINA HEALTHCARE SARL | Tanzania | 1 | $568.40 | SHALINA LABORATORIES… | Syrup |
| 24 | SURGIPHARM LTD | Kenya | 1 | $191.55 | IND SWIFT LTD | Tablet |
| 25 | TORRENT DO BRASIL LTDA | Brazil | 1 | $44.29 | TORRENT PHARMACEUTIC… | Tablet |
| 26 | EMIRATES POST GROUP | United Arab Emirates | 9 | $7.28 | MOVID IMPEX | Tablet |
This report covers 97 2025-Q4 Citalopram shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/citalopram
Talk to our trade analyst
Need a custom citalopram report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/citalopram
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Citalopram product page
Live data, supplier directory, price trends, and trade route analysis